

238 Monographs set forth an article's nonproprietary name, definition, specification and may
239 include other requirements such as packaging and storage. The specification consists of
240 tests, procedures and acceptance criteria that define the identity, strength, quality and
241 purity of the monographed material. Pharmacopoeial monographs provide an important
242 tool for assuring of the safety and efficacy of marketed medicinal ingredients and
243 products through testing of their quality. Thus, a medicinal product may be tested at any
244 point in the time when it is legally marketed with a pharmacopoeial monograph to assure
245 its compliance with the monograph.

246
247 Pharmacopoeial monographs may cover the medicinal product itself, its ingredients and
248 associated materials. Pharmacopoeial monographs may include additional information
249 related to allied components, such as process (e.g. a preparation monograph to guide
250 compounding practitioners).

251
252 Pharmacopoeial monographs allow manufacturers, compounding professionals,
253 purchasers, governmental bodies and others independent of sellers and buyers to test the
254 quality of the ingredients and associated materials of a medicine and the medicine itself
255 in its packaging.

256
257 Pharmacopoeial standards allow independent testing and are a critical part of the “safety
258 net” of standards that help ensure the quality, safety and efficacy of medicines. They are
259 closely allied with good manufacturing practice standards, which are process standards.

260
261 Pharmacopoeial monographs generally cover chemical and biological medicines and their
262 ingredients approved by national regulatory authorities or otherwise legally marketed
263 within a national or regional sphere of control. Some pharmacopoeias also include
264 standards for herbal medicines and nutritional ingredients and products.

265
266 Pharmacopoeial monograph procedures often call for reference standards, which are
267 developed and made available for distribution by the pharmacopoeia (see section 4 on
268 Reference Standards).

269

270 **General principles**

271

272 (a) Pharmacopoeial standards should be available for marketed medicines and their
273 ingredients and associated materials.

274

275 (b) Public pharmacopoeial standards are science-based and data-driven and based on
276 sound measurement and allied sciences.

277

278 (c) Pharmacopoeias respect the intellectual property of considerations of donors and
279 recognize the importance of maintaining the confidentiality of proprietary third-party
280 information. A pharmacopoeia's core mission is to create public standards to help ensure
281 the quality of medicines. Pharmacopoeias hope to work collaboratively with
282 manufacturers and regulators in the development of public standards.

283

284 **General chapters**

285

286 General chapters may contain the following:

287

288 (i) Descriptions of tests and procedures for application through individual
289 monographs;

290 (ii) Information for the interpretation of the compendial requirements and
291 explanations of terms, definitions, and symbols (if any);

292 (iii) Descriptions of general pharmaceutical storage, dispensing and packaging
293 practices;

294 (iv) General guidance to manufacturers of official substances or official
295 products;

296 (v) Descriptions and specifications of conditions and practices for
297 pharmaceutical compounding.

298

299 When a general chapter is referenced in a monograph, acceptance criteria specified in the
300 general chapter should be followed unless otherwise specified in the monograph. Some
301 general chapters may serve as introductory overviews of a test or of analytical techniques.
302 They may reference other general chapters that contain techniques, details of the
303 procedures and, at times, acceptance criteria. At times, general chapters may be grouped
304 by topic for ease of use, given that they speak to a broad category of monographs, e.g.
305 chemical drug substances.

306

307 Adoption of pharmacopoeial standards

308

309 (a) Text in a pharmacopoeial monograph or general chapter is approved by an expert
310 body of the pharmacopoeia, following publicly available rules and procedures, including
311 applicable conflict of interest and confidentiality rules.

312

313 (b) Reference materials cited in a monograph and/or their compendial uses also are
314 approved by a pharmacopoeial expert body.

315

316 (c) At times, pharmacopoeial experts may elect not to set a standard for a particular
317 medicinal product.

318

319 Open and transparent process

320

321 (a) Pharmacopoeias ensure openness and transparency throughout the development of
322 pharmacopoeial standards, which includes:

323

324 (i) Development, revision and, in the absence of a public health emergency or
325 other urgent need for expedited action, public notice with adequate time for
326 review and comment from impacted stakeholders;

327

328 (ii) Rapid correction of errors published in compendial text, when necessary;

329

330 (iv) Timely and appropriate revision and/or withdrawal of compendial
331 standards, when necessary.

332

333 **Continuous revision**

334

335 (a) Pharmacopoeial standards are in a continuous revision process to ensure that they
336 are based on current scientific knowledge. Pharmacopoeias can prioritize monograph
337 updating based on factors such as prevalence of use, toxicological data, evolving scientific
338 techniques and technologies, requests from a regulatory authority or other stakeholder and
339 emergent public health issues.

340

341 **Harmonization**

342

343 Pharmacopoeias should harmonize standards wherever possible, through monographs and
344 general chapters. Harmonization may occur through several processes including:
345 revision of a standard between two pharmacopoeias (bilateral harmonization);
346 development of a new standard through coordinated consideration of a single submission
347 (prospective harmonization); revision or creation of standards through a coordinating
348 body (PDG and ICH) or others.

349

350 **Legal recognition**

351

352 Pharmacopoeial monographs may acquire legal status and then become subject to
353 enforcement depending on applicable national or regional requirements.

354

355 **Conformance with a pharmacopoeial monograph**

356

357 A pharmacopoeial medicinal product is considered to be in conformance with a
358 monograph when: (1) the name and identity conform to those provided in the
359 pharmacopoeial monograph; (2) the article complies with all relevant procedures in the
360 pharmacopoeia; and (3) is analyzed using the reference standard(s) specified in the

361 pharmacopoeial monograph.

362

363 Acceptance criteria

364

365 Acceptance criteria are numerical limits, ranges, or other suitable measures for
366 acceptance of the results of analytical science to allow determination of pass/fail criteria.
367 Acceptance criteria indicated in a pharmacopoeial monograph may allow for analytical
368 error, for unavoidable variations in manufacturing processes and for deviations to an
369 extent considered acceptable under practical storage conditions. They provide standards
370 with which substances or products must comply throughout their shelf life.

371

372

373 3.2 Technical guidance

374

375 3.2 Technical guidance

376

377 *3.2.1 Monographs for pharmaceutical substances, including active pharmaceutical*
378 *ingredients and excipients [as received from Ph.Eur., BP, Russian*
379 *Pharmacopoeia, USP]*

380

381 Prior to the preparation of any monograph, it is essential to gather as much information as
382 possible on the substance in question.

383

384 In particular it is necessary to ascertain:

385

- 386
- whether the substance is of natural, synthetic or semi-synthetic origin;
 - 387 • whether the substance is a mixture or a single entity;
 - 388 • the method(s) of preparation of the substance;
 - 389 • whether there are differences in physical form, for example, crystallinity since the
390 properties of the substance may vary in accordance with this parameter;

- 391 • whether a single chemical isomer (e.g. enantiomer) as well as mixtures of isomers
392 (e.g. racemate) are available;
- 393 • whether different hydrates are available;
- 394 • whether different entities (acid, base, salt, etc.) are available.

395

396 Substances that are to be described in a monograph may be members of a group of very
397 similar substances (family). This holds true especially for excipients such as macrogols.
398 A master monograph is to be drafted clearly stating the attributes common to all members
399 of the family and that can be used to identify single members of the family (family
400 monograph).

3.2.1.1 *Monograph title*

401 The International Nonproprietary Name (INN) established by WHO should be considered
402 for use wherever it is available, while recognizing that individual pharmacopoeias may
403 apply their own nomenclature policies. Where the INN is used, it is supplemented as
404 appropriate by the name of the anion or cation and by “hydrate”, “dihydrate”, “hydrated”
405 (for ill-defined degrees of hydration) or “anhydrous” (where a hydrated form is also
406 known to exist). Anions and cations are indicated as “mono-”, “di-”, “tri-”, etc., as
407 appropriate. Where a substance is used in approved medicinal products for veterinary use
408 only, “for veterinary use” is included in the title.

3.2.1.2 *Definition*

- 409 • Graphic formula. The recommendations of WHO on the drawing of structures are
410 normally followed.
- 411 • Empirical formula and relative molecular mass. The latter is calculated based on
412 the figures of the International Table of Relative Atomic Masses.
- 413 • CAS (Chemical Abstracts Service) number.

414 • Chemical name. The chemical names are based on the rules of the International
415 Union of Pure and Applied Chemistry (IUPAC). In addition, non-IUPAC names
416 may also be indicated.

417

418 This implies investigating in particular:

419 - the possible existence of isomers so as to be able to specify which isomer
420 is used or, otherwise, to state that the product is a mixture of isomers;

421 - in the case of an optical isomer, the absolute configuration is given by the
422 *R/S* system at the asymmetrical centre(s) or any other appropriate system
423 (e.g. for carbohydrates and amino acids);

424 - ascertaining the state of hydration or solvation so as to distinguish clearly
425 between the well-defined hydrates and solvates and the products that
426 contain variable quantities of solvent(s). As regards the former, water or
427 solvent content ranges are specified but for the latter only a maximum
428 content is given. When a substance exists both in a water-free or solvent-
429 free form and in the form of (a) hydrate(s) or (a) solvate(s) with different
430 water or solvent contents, and if all these forms are used, they are
431 normally treated as individual substances requiring separate monographs.

432

433 Some chemical substances, particularly those obtained from raw materials of natural
434 origin and substances produced by fermentation, may not be easily separated from certain
435 related substances (for instance, quinine salts). These may be treated as:

436

437 • a chemical product when obtained in a very pure state and when they can be
438 assayed by a physicochemical method;

439 • a substance accompanied by a certain proportion of related substances, giving an
440 exact definition of the main component only (e.g. neomycin);

441 • a mixture of several components, sometimes difficult to define, where an overall
442 description may suffice (e.g. nystatin).

443

444 Where applicable, the origin of the substance is specified (name and strain of the
445 organism from which the substance is derived). Where applicable, the monograph
446 indicates that the substance is semi-synthetic and derived from a fermentation product.

447 3.2.1.2.1 *Combinations*

448 In therapeutics, more or less well-defined chemical combinations (for instance,
449 theophylline-ethylenediamine) or even mixtures are sometimes used. In such cases, it is
450 necessary to specify precisely each component of the combination or mixture, with its
451 chemical structure and the proportion in which it is present.

452 3.2.1.3 *Content*

453 Assay limits are specified between which the content falls. The content may be also
454 defined in a one-sided manner. The assay limits take account of the precision of the
455 method as well as the acceptable purity of the substance. Assay limits are normally
456 expressed with reference to the dried or anhydrous/solvent-free substance.

457

458 For a non-specific assay (for example, titrimetry) the assay limits are usually 99.0-
459 101.0 % (unless otherwise justified). For a specific assay using a separation technique
460 (for example, liquid or gas chromatography), the upper assay limit is normally 102.0 %;
461 the lower assay limit will take any necessary account of the impurities present and may
462 therefore be lower than 98.0 %.

463

464 In setting these limits for the active ingredient content, account is taken of:

465

- 466 • the method of preparation, which determines the degree of purity that may be
467 reasonably required;
- 468 • the reproducibility and accuracy of the analytical method;
- 469 • where a separation technique is employed both for the test for related substances
470 and the assay, content limits are set taking into account the maximum permitted
471 amount of impurities and the analytical error;

- 472 • the evaluation of the tolerable degree of deterioration during storage (since the
473 limits are intended to apply throughout the shelf life of the substance and not just
474 at the time of testing);
- 475 • a sufficient number of experimental results obtained on several batches (at least 3),
476 if possible, of different origins and ages.

477

478 In cases where the water content is high (e.g. in the case of disodium phosphate
479 dodecahydrate), limits of content may be expressed with reference to the hydrated
480 substance, taking into account the molecular mass of the hydrated form (only for well-
481 defined and stable hydrates) or with reference to the substance “as is” in combination
482 with determination of water content/loss on drying.

483

484 When the substance to be examined contains a relatively large proportion (a few %) of
485 impurities, which are determined at the same time as the active ingredient, an appropriate
486 wording is to be used (for instance, in the case of quinine salts: “x % of total alkaloid
487 salts, expressed as quinine salts”).

488

489 Exceptionally reference is made to only a part of the molecule or to an element (for
490 example, assay of magnesium oxide in light magnesium carbonate or assay of
491 magnesium in magnesium stearate).

492

493 In the case of antibiotics determined by microbiological assay, the activity is expressed in
494 International Units, where these exist, and only a minimum value is given.

495 See also section Assay.

3.2.1.4 *Characters*

496 The statements under the heading Characters are not to be interpreted in a strict sense and
497 are not regarded as analytical requirements. Caution statements may be included here.

498

499 The principal items that may be referred to under this heading are the following.

500 3.2.1.4.1 *Appearance*

501 This description will normally embrace colour and physical form.

502

503 3.2.1.4.2 *Taste*

504 The taste is not to be taken into consideration for safety reasons.

505 3.2.1.4.3 *Odour*

506 In general, no reference is made to odour – with the exception of substances
507 having specific odour (methyl salicylate, camphor, menthol, etc.). In particular no
508 reference to odour is made for those materials that would constitute a hazard if inhaled.
509 Mention of odour in other cases is justified. Odour may also serve as a sign of the
510 substance good quality, because the appearance of foreign odour may speak of the
511 substance degradation (e.g. acetic acid in acetylsalicylic acid, cacao butter, etc.).

512

513 3.2.1.4.4 *Solubility*

514 All solubilities are quoted in general terms. A method recommended for the estimation of
515 solubility is given in a general chapter/method. Solvents quoted usually include water, an
516 alcohol and a lipophilic solvent.

517

518 In special cases the solubility of different samples of a material may vary rather
519 considerably even though their composition is still within the limits set by the monograph.
520 The solubilities in the solvents thereby affected are then given to cover more than one
521 solubility class, e.g. “sparingly soluble to soluble in ...”.

522 3.2.1.4.5 *Stability factors*

523 Evidence of instability due to exposure to air, light and for moisture is to be given,
524 e.g. physostigmine sulfate turns red when exposed to air and light.

525 3.2.1.4.6 *Hygroscopicity*

526 Some substances are hygroscopic (they deliquesce, dampen or dissolve). In such cases,
527 this is indicated for information of the analyst as an alert for precautions to be taken in

528 handling the substance. A method recommended for the determination of the tendency of
529 a substance to take up atmospheric water is given in a general chapter/method.

530

531 Where a substance is described under Characters as hygroscopic or deliquescent, storage
532 in an airtight container is indicated.

533 3.2.1.4.7 *Solid-state properties*

534 Solid-state properties include crystallinity, polymorphism, density of solids, particle size
535 of solids and specific surface area of solids. A method recommended for the
536 determination of crystallinity is given in a general chapter/method.

537

538 Solid-state properties of excipients that are relevant for functionality may be dealt with in
539 the Tests section.

540

541 When polymorphism is known to exist in the substance, this information is given as a
542 separate statement (“it shows polymorphism”). This statement is intended to alert users to
543 the need to evaluate this phenomenon during the development of a dosage form.

544

545 Two cases are to be distinguished when polymorphism is known to exist:

- 546 • usually, the monograph does not exclude any of the possible crystalline forms;
- 547 • exceptionally, if the substance is only used in solid dosage forms and one form
548 has been shown to be preferred from the point of view of bioavailability or to
549 have a better safety/efficacy profile, then the monograph may be limited to that
550 form. The techniques required to identify the form are included in the monograph,
551 typically in the Identification section.

552 3.2.1.4.8 *Other characteristics*

553 Other physical characteristics that may be useful as information may be stated under the
554 heading Characters. This will usually apply to a melting point that is insufficiently
555 precise to allow a range to be quoted (“about X°C”). When decomposition may occur,
556 this is stated (“about X°C (with decomposition)”).

3.2.1.5 Identification

557 3.2.1.5.1 General

558 The purpose of the Identification section of a monograph is to provide a means for
559 confirming that the substance in question is indeed the article named in the monograph.
560 The physical and/or chemical tests and reactions, when taken together, that enter into the
561 Identification section ensure, as far as possible, specificity. The specificity of the
562 identification should be such that active substances and excipients exhibiting similar
563 structures are distinguished. When an identification series is being investigated, it is
564 desirable that other similar substances, whether or not they are the subject of monographs
565 of the Pharmacopoeia, are examined at the same time to ensure that a particular
566 combination of tests within a series will successfully distinguish one similar substance
567 from another. They are not to be too sensitive, i.e. false reactions caused by the presence
568 of tolerated impurities are to be avoided.

569

570 Some of the purity tests in a monograph may also be suitable for identification purposes,
571 possibly in a modified form. A system of cross-reference to the TESTS section(s) can be
572 exploited. This is particularly relevant in cases where distinction between closely related
573 materials depends on properties that are also parameters in purity or composition control,
574 e.g. water content of different hydrates, optical rotation of different isomers, enantiomeric
575 purity, viscosity of chain-length homologues of a polymer.

576

577 In the case of a family monograph, identification of the type of substances may be
578 supplemented by non-specific but discriminating tests to identify individual members of
579 the family.

580

581 Examples are given below of some methods of identification and they are followed by
582 detailed guidelines concerning some of them.

583 3.2.1.5.2 Methods requiring complex instrumentation

- 584 • Spectrophotometric analysis, such as recording of infrared or nuclear magnetic
585 resonance spectra.

586 • Chromatographic examination by means of gas chromatography (GC) or liquid
587 chromatography (LC).

588 3.2.1.5.3 *Other methods*

589 • Determination of physical constants such as melting point, freezing point, boiling
590 point, specific optical rotation, angle of rotation, ultraviolet spectrum, specific
591 absorbance, relative density, refractive index and viscosity.

592 • Chemical reactions such as colour or precipitation reactions (including formation
593 of derivatives or degradation products, which may subsequently be subjected to
594 physical examination) and determination of chemical values (saponification, ester,
595 hydroxyl and iodine values).

596 • Chromatographic examination by thin-layer chromatography (TLC).

597 3.2.1.5.4 *Infrared absorption spectrophotometry*

598 This is generally considered to be a satisfactory single method for verification of the
599 identity of non-ionized organic substances other than salts of organic acids or bases. This
600 method always necessitates the use of a reference substance or a reference spectrum.
601 Reference substances are preferred to reference spectra.

602
603 Organic salts of organic substances and some inorganic salts of organic substances
604 (e.g. phosphates and sulfates) can readily be distinguished from each other.

605
606 The method of sample preparation (disk, halide salt plate, mull, etc.) might not be
607 specified unless this has been found to be necessary during the development of the
608 monograph to obtain a satisfactory spectrum.

609
610 In certain cases, there is a need to supplement the infrared spectrum with other tests
611 where the spectrum alone is insufficient for confirmation of identity, as follows.

612
613

614 3.2.1.5.4.1 Salts of organic acids or bases

615 Ions are usually identified using one of the commonly applied identification reactions
616 described in a general method.

617 3.2.1.5.4.2 Chemically related substances

618 When substances closely related to the substance under examination exhibit variations in
619 the spectra that are considered insufficient for unambiguous identification, the infrared
620 spectra are accompanied by another simple test, e.g. melting point or thin-layer
621 chromatography.

622 3.2.1.5.4.3 Polymorphism

623 Where a monograph mentions polymorphism, a method for recrystallization is described
624 unless it is the intention to limit the scope of the monograph to the crystalline form
625 represented by the chemical reference substance. In the latter case the monograph
626 indicates that the spectrum is recorded “without recrystallization”.

627

628 Exceptionally, when the monograph describes a specific crystalline form or forms and
629 when the IR spectrum is not characteristic, an additional test is introduced.

630 3.2.1.5.4.4 Optical isomers

631 To identify a particular isomer or a racemate, a test for optical rotation is given in the
632 IDENTIFICATION section or a cross-reference is made to a test for enantiomeric purity or
633 optical rotation in the TESTS section.

634 3.2.1.5.5 *Ultraviolet and visible absorption spectrophotometry*

635 This method is usually non-specific for identification purposes, unlike infrared
636 spectrophotometry, unless the absorption curve exhibits several maxima and minima,
637 unusually strong or weak regions of absorption, etc. Reference substances are generally
638 not used. The UV spectrum of a substance can, therefore, seldom stand on its own as an
639 identification criterion.

640

641 The concentration of the solution to be examined is such that the absorbance preferably
642 lies above 0.5, measured in a 1 cm cell.

643

644 The range of wavelengths to be explored is stated; generally it does not extend towards
645 the region where end-absorption and solvent interference may be expected.

646

647 Care is taken in the choice of solvents and solvent purity prescribed for ultraviolet
648 spectrophotometry in order to avoid the presence of impurities, which may influence the
649 absorbance of the substances to be examined.

650

651 In certain cases of identification by means of absorption spectra in the UV-visible range,
652 the resolution of the instrument can be expected to constitute a critical factor in observing
653 the required spectral features (e.g. benzenoid-type spectra showing a fine structure). In
654 certain cases the minimum resolution required is indicated in the monograph.

655 *3.2.1.5.6 Melting temperature, freezing temperature and boiling temperature*

656 These physical constants are of value in identification only if they are well defined and
657 their determination is not accompanied by destruction to a degree that renders them
658 extremely dependent on the actual mode of operation. The possible existence of
659 polymorphism is also be taken into account.

660

661 Neither the melting point alone nor the addition of a chemical reaction is sufficient to
662 confirm identity of a substance. However, the addition of another identification test such
663 as TLC will often suffice.

664 *3.2.1.5.7 Optical rotation*

665 When an enantiomer is described in a monograph, a test for optical rotation is given in
666 the IDENTIFICATION section or a cross-reference is made to the TESTS section which
667 contains either a test for enantiomeric purity or a test for optical rotation.. When both the
668 racemate (or the racemic mixture) and the enantiomer are available then, in the
669 monograph of the racemate, the verification of the angle of rotation will be given in the
670 TESTS section and will be referred to in the IDENTIFICATION section. When only the

671 racemate is available the verification of the angle of rotation will be given in the TESTS
672 section, provided the specific optical rotation of the chiral form is known and is of
673 sufficient magnitude to provide a meaningful test for racemic character.

674 3.2.1.5.8 *Thin-layer chromatography (TLC and HP-TLC)*

675 This identification method requires the use of reference substances. Selectivity may be
676 improved by combining thin-layer chromatography with chemical reactions in situ, i.e. by
677 employing appropriate spray reagents. In the latter case, the same or a similar reaction is
678 not to be repeated on a test-tube scale.

679

680 During development and validation, separation of the substance from structurally similar
681 substances is demonstrated.

682 3.2.1.5.9 *Gas chromatography and liquid chromatography*

683 Gas and liquid chromatography are used for identification only when applied elsewhere
684 in the monograph (in a test or the assay). These methods are used if there is no suitable
685 alternative and should not be used as a sole identification test.

686 3.2.1.5.10 *Chemical reactions*

687 Commonly applied identification reactions of a chemical nature are described in a general
688 method and are to be used whenever appropriate. Each chemical reaction is to be chosen
689 to demonstrate the presence of a different part of the molecule to be identified.

690 Identification criteria that call for the recognition of an odour or a taste are to be avoided.

691 To differentiate substances within a group (family) which differ by:

- 692 • the extent of condensation;
- 693 • the length of the hydrocarbon chain (e.g. fatty acids),

694

695 it is necessary to cross-reference to the appropriate purity test(s) where values are
696 determined (e.g. iodine value, saponification value, etc.).

3.2.1.6 Other tests

697 3.2.1.6.1 *General*

698 The Tests section is principally directed at limiting impurities in chemical substances.
699 While it is an essential function of the monograph to ensure adequate purity in the
700 interests of public health, it is not the aim of the pharmacopoeia to impose excessive
701 requirements that restrict unnecessarily the ability of manufacturers to produce compliant
702 products.

703
704 In the interests of transparency, information is included wherever possible on: the
705 impurities controlled by a test; the approximate equivalent (percentage, ppm, etc.) of the
706 prescribed limit in terms of the defined impurities or class of impurities.

707
708 Certain tests may apply to special grades (parenteral, dialysis solutions, etc.) or a test may
709 have a special limit for a particular use: the particular application of a test/limit is
710 indicated within the test.

711 3.2.1.6.2 *Titles*

712 Wherever possible, the title includes the impurity or class of impurities limited by the test.
713 Non-specific tests carry a more general title appropriately chosen from the standard
714 terminology of the pharmacopoeia or a similar designation.

715 3.2.1.6.3 *Solutions*

716 The solvent used and the concentration chosen depend on the solubility of the substance
717 to be examined and the purpose for which the test is intended. The quantity of solution
718 prepared is sufficient to carry out each of the tests for which it has been prepared.
719 Depending on the particular tests, the concentration of a solution is defined with varying
720 precision.

721 3.2.1.6.4 *Appearance of solution*

722 This test makes it possible to ascertain the general purity of a substance by the detection
723 of impurities insoluble in the solvent selected, or of coloured impurities.

724

725 The “Appearance of solution” test is normally prescribed for substances intended for
726 preparations for parenteral use. Apart from this, it is to be applied only if it yields useful
727 information concerning the general purity/stability of the substance which is not obtained
728 by other tests of the monograph.

729

730 It can comprise the verification of the clarity/degree of opalescence of the solution and/or
731 the verification of the degree of its coloration. Corresponding methods are described in
732 general methods.

733

734 The solvent employed is usually water but other solvents may be preferred depending on
735 the solubility of the substance to be examined.

736

737 When an organic solvent is used to prepare the solution, it may be necessary to ensure
738 that the solvent also complies with the test, especially where there is a very stringent
739 requirement.

740

741 The more concentrated the solution the stricter the test. For very pure substances or those
742 used in high doses, the concentration chosen is 50 to 100 g/L, whereas for less pure
743 substances or substances administered in small doses the concentration is 10 to 20 g/L.

744 3.2.1.6.4.1 Clarity and degree of opalescence

745 This test is mainly performed on colourless substances or those that give only slightly
746 coloured solutions in order to permit valid comparison with reference suspensions.

747 3.2.1.6.4.2 Degree of coloration

748 The test applies to essentially colourless substances that contain, or may degrade to form,
749 coloured impurities that can be controlled by limiting the colour of solution of the
750 substance.

751

752 An appropriate reference solution is given for comparison. When the shade of colour
753 varies according to the samples, 2 or more reference solutions of the same degree of

754 colour may be mentioned, or even only the degree of coloration without specifying the
755 actual colour.

756

757 For material intended for parenteral use and for highly coloured solutions, it is often
758 preferable to apply a limit of absorbance measured with a spectrophotometer at a suitable
759 wavelength (usually between 400 and 450 nm). The concentration of the solution and the
760 limit of absorbance are stated. The conditions and limit are based on knowledge of the
761 absorbance curve in the range defined and on results obtained with appropriate samples,
762 including stored and degraded samples, as necessary.

763 3.2.1.6.5 *pH and acidity or alkalinity*

764 This test allows the limitation of acidic or alkaline impurities stemming from the method
765 of preparation or purification or arising from degradation (e.g. from inappropriate
766 storage) of the substance. The test may also be used to verify the stoichiometric
767 composition of certain salts.

768

769 Two types of test for protolytic impurities are used:

- 770 • pH measurement or
- 771 • Acidity or alkalinity test (a semi-quantitative titration experiment using indicators
772 or electrometric methods to define the limits).

773

774 pH measurement is included if the material has buffering properties, otherwise a
775 titrimetric procedure is recommended. If, the addition of standard acid/or base results in
776 decomposition or precipitation of the substance to be examined, it may be necessary to
777 prescribe a pH test regardless of the buffering properties.

778 3.2.1.6.6 *Optical rotation*

779 The optical rotation test, though sometimes useful for identification purposes, is mainly
780 used as a purity test:

- 781 • either to assess the general purity of an optically active substance (a liquid or a
782 solid in solution), by calculating the specific optical rotation;

783 • or to limit the presence of optically active impurities in any optically inactive
784 substance (racemate or racemic mixtures), provided that the specific optical
785 rotation at 589.3 nm is sufficient to ensure adequate sensitivity. In this case the
786 range normally given should be $- 0.10^\circ$ to $+ 0.10^\circ$ (covering the substances that
787 are not true racemates). In this case the angle of rotation of the liquid or of a
788 solution of the solid, is measured under defined conditions.

789

790 It is usually more appropriate to control these impurities by chiral separation methods
791 since the specific optical rotation is often insufficient to limit the presence of the
792 unwanted enantiomer in the presence of the active enantiomer.

793

794 The test is not suitable for highly coloured or opalescent solutions (in the latter case a
795 filtration can sometimes make the determination possible).

796

797 The concentration of the solution: is chosen to be high enough to give a reliable reading
798 of the angle of rotation. The degree of hydration or organic solvation of the substance is
799 taken into account in calculating the result.

800 3.2.1.6.7 *Absorption spectrophotometry (ultraviolet and visible)*

801 The absorption of electromagnetic radiation may be used in purity tests as a limit test for
802 certain impurities. The typical case is that of impurities that absorb in a region where the
803 substance to be examined is transparent. This test may be performed by direct
804 measurement on a solution, or after carrying out a chemical reaction that forms, with the
805 impurity, a substance that absorbs at a wavelength where the substance to be examined is
806 transparent.

807

808 For measurements in the ultraviolet, it is advisable not to measure below 230 nm.

809